GOTHENBURG, Sweden--(BUSINESS WIRE)--The Swedish medical solutions company, Mölnlycke Health Care, today announced a licensing agreement with the Texas-based biomedical R&D company, Rochal Industries. The collaboration will initially focus on the introduction of novel skin care products to strengthen Mölnlycke’s current skin care offer and further reinforce its position as a world-leading prevention solutions company.
The two companies have also signed a joint development agreement for future products and will be able to leverage on each other’s R&D strengths.
The licensing agreement between Mölnlycke Health Care and Rochal Industries, initially consists of private labeled skin protectant products, including a next generation antimicrobial barrier film. Skin protectants play a major role in preventing and treating Incontinence Related Dermatitis (IAD), which can be a factor in pressure ulcer development.
The product line will enhance Mölnlycke’s skin care assortment and full portfolio designed for pressure ulcer prevention. The portfolio, includes wound dressings with Safetac® technology, and patient positioning solutions, and will give Mölnlycke further competitive edge in the area.
The collaboration also includes the two companies entering into joint development on future products and gives Mölnlycke access to Rochal’s technical expertise. Rochal will develop commercially viable innovations in conjunction with Mölnlycke, who in turn will drive the commercialization of further new patented platform technologies.
“Skin protectants are strategically important to our Prevention solution offer and the partnership with Rochal enables us to provide our customers with a complete solution within the pressure ulcer prevention area. Rochal has a strong track record of inventing, protecting and licensing valuable IP and we see great potential for future products through the exchange of competence and experience. We are looking forward to a long-lasting and productive commercial partnership.” – Richard Twomey, CEO, Mölnlycke Health Care.
“The emergent products Rochal has developed for protecting skin including the antimicrobial barrier film are patent protected technological innovations that we are excited to have Mölnlycke bring to the market. Their focus on patient well-being and wound and skin care expertise will result in improved outcomes for patients, care givers, clinicians and providers.” – Ann Beal Salamone, CEO Rochal Industries LLC.
Mölnlycke Health Care
Mölnlycke Health Care is a world-leading medical products and solutions company that equips healthcare professionals to achieve the best patient, clinical and economic outcomes. We design and supply products and solutions for use in wound treatment, pressure ulcer and infection prevention and surgery. Our products and solutions provide value for money supported by clinical and health economic evidence.
Mölnlycke Health Care employs around 7,500 people and is owned by Investor AB. The company headquarters are in Gothenburg, Sweden and we operate in 90 countries worldwide. For more information, please visit www.molnlycke.com.
Rochal Industries LLC
Rochal Industries based in San Antonio, Texas is a global leader in creating technology innovations in polymer, antimicrobial, biological systems and related fields. Rochal is partnered with the Catalyst Group Inc, (a Houston-based private equity firm) and Atteris Healthcare. Atteris is committed to finding the best go to market solutions for Rochal’s technologies including licensing, direct to market, and acquisitions depending on the technology and clearances for the products. Please visit us at www.rochalindustries.com or www.atterishealthcare.com.
This information was brought to you by Cision http://news.cision.com
Contacts
Mölnlycke Health Care
Bodil Czarnecki, Global Manager, Corporate Communications
E-mail: bodil.czarnecki@molnlycke.com
Tel: +46 (0) 739 41 25 37
